Health ❯ Healthcare ❯ Chronic Conditions

Diabetes

Type 2 Diabetes Type 1 Diabetes GLP-1 Drugs Insulin Management Weight Management Management Strategies Blood Sugar Management Medication Effects GLP-1 Medications GLP-1 Receptor Agonists

GLP-1 Weight-Loss Boom Is Reshaping Diets as Experts Urge Lifestyle Support

Food companies report falling sugar demand with the spread of Ozempic-class drugs.

UK Regulator Adds Rare Vision‑Loss Warning to Ozempic, Wegovy and Rybelsus

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

FDA Recalls Specific FreeStyle Libre 3 Sensors Over Faulty Low-Glucose Readings

PAMI Confirms 100% Drug Coverage Program as February List Is Published

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

New Review Finds Rapid Weight Return After Stopping GLP-1 Weight-Loss Drugs

After-Meal Blood Sugar Spikes Tied to 69% Higher Alzheimer’s Risk, Large Genetic Study Finds

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

Investigation Finds Banned Insulin Still Dispensed in Peru Despite Recall Order

NHS and Pharmacies Urge Immediate Repeat Prescription Orders Ahead of Holiday Closures

Recalls Expand for Abbott FreeStyle Libre 3 Sensors Over False Low Readings

Brazil Expands Use of Mounjaro: Dentists Cleared to Prescribe as Vilhena Rolls Out Free Treatment

FDA Issues Early Alert on Certain FreeStyle Libre 3 Sensors After False Low Readings Linked to Harm

Abbott Recalls FreeStyle Libre 3 Sensors in 17 Countries After Reports of False Low Readings

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

Denmark Awards Compensation to Four Patients for Eye Damage Linked to Ozempic and Wegovy

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

KFF Poll: GLP-1 Use Hits 12% of U.S. Adults as Cost Burdens Persist